Laboratorio Reig Jofre, S.A. · BME:RJF

Laboratorio Reig Jofre — H1 2015 Earnings Presentation

22 slides from Laboratorio Reig Jofre's earnings presentation, Jul 30, 2015

  1. Slide 1: H1 2015 Results Presentation

    H1 2015 Audio webcast RESULTS PRESENTATION July 30, 2015

  2. Slide 2: Disclosure

    DISCLOSURE This presentation contains no confidential material and may include publicly available market information which has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. Information in this presentation should not be

  3. Slide 3: Contents

    CONTENTS 1. HALF YEAR HIGHLIGHTS 02. BUSINESS PERFORMANCE Turnover and EBITDA Financial results Business areas Markets 03. STRATEGIC FOCUS FOR THE FUTURE 04. THE SHARE Share performance and reverse split 05. FINANCIAL STATEMENTS 06. LINKS TO COMPLEMENTARY INFO

  4. Slide 4: Half Year Highlights

    1. HALF YEAR HIGHLIGHTS

  5. Slide 5: Half Year Highlights

    HALF YEAR HIGHLIGHTS  +2.6% turnover to 81.5 M€ following general growth of RJF Pharma P&L despite sales decrease of RJF CDMO  +5.5% EBITDA to 10.6 M€ and 13.0% EBITDA margin  +6.3% profit before taxes to 8.2 M€  +16.6% net profit to 7.2 M€  Significant seasonality of the food supplements busin

  6. Slide 6: Business Performance

    2. BUSINESS PERFORMANCE

  7. Slide 7: Turnover and EBITDA

    TURNOVER AND EBITDA TURNOVER. In million euro EBITDA. In million euro +2.6% +5.5% 90 80 81.5 70 79.4 60 50 40 30 13.0% 12.7% 20 10 0 6M 2014 6M 2015 proforma consolidated EBITDA margin  Turnover in H1 2015 grew by 2.6% to 81.5 M€ driven by RJF Pharma business unit, which accounted for 80% of the to

  8. Slide 8: Financial Results

    FINANCIAL RESULTS NET RESULT. In million euro H1 2014 H1 2015 Evol. +16.6% (in euro) proforma consolidated 10 Turnover 79,446,149 81,493,618 2.6% Gross margin 51,159,420 51,577,635 0.8% Operating expenses -41,097,381 -40,961,578 0.3% EBITDA 10,062,039 10,616,057 5.5% 7.2 % sales 12.7% 13.0% 5 6.2 Am

  9. Slide 9: Business Areas

    BUSINESS AREAS Acceleration of RJF PHARMA by leveraging on R&D +2.6% H1 2015 RJF PHARMA RJF CDMO turnover: (Own development’s manufacture (Specialised contract development and and sale) manufacturing) 81.5 M€ 80% 20% 65.6 M€ 15.9 M€ TURNOVER BY BUSINESS AREAS In million euro 70 +6.6% RJF PHARMA 60 6

  10. Slide 10: Business Areas: Product categories of RJF Pharma

    BUSINESS AREAS Good performance of all product categories of RJF PHARMA 80% RJF PHARMA RJF CDMO (Own development’s manufacture (Specialised contract development and and sale) manufacturing) 65.6 M€ SPECIALISED-TECHNOLOGY SPECIALTY PRODUCTS FOOD SUPPLEMENTS AND PRODUCTS CONSUMER HEALTHCARE Dermatolog

  11. Slide 11: Markets

    MARKETS 94% of sales grow over 6% DIRECT SALES Spain France Nordic countries Benelux Portugal  RJF’s top-10 markets outside UK Spain are: France, United Kingdom, Sweden, Germany, Belgium, Italy, Spain OVER 100 COMMERCIAL Holland, Greece, Portugal and 41.1% PARTNERS IN 50 Saudi Arabia, which togethe

  12. Slide 12: Markets: Recent progress in new markets

    MARKETS Recent progress in new markets UNITED KINGDOM SOUTHEAST ASIA  Acquisition of marketing authorisations of 4 derma products  Creation of joint-venture in Singapore focus in high-  Investment: £3.6 M. Full- growth regional markets JAPAN (Burma, Cambodia, Laos). year recurring sales of aprox.

  13. Slide 13: Strategic Focus for the Future

    3. STRATEGIC FOCUS FOR THE FUTURE

  14. Slide 14: Strategic Focus for the Future

    STRATEGIC FOCUS FOR THE FUTURE Projects within at least two of the four strategic pillars R&D Development of:  New indications and/or dosage forms of known active principles  Generic products with special focus on beta lactam and freeze-dried injectable antibiotics  Topical dermatological product

  15. Slide 15: The Share

    4. THE SHARE

  16. Slide 16: Share Performance and Reverse Split

    SHARE PERFORMANCE AND REVERSE SPLIT +2.6% 6M 2015 0.257 RJF: +39.7% 0.184 SmallCap: +18.8% Ibex35: +4.8% DAX (Germany): 12.1% CAC 40 (France): 12.6% Euro Stoxx 50: 9.1% Euro Stoxx Pharma: 15.1% Market Cap: 325 M€ Q1 2015 Q2 2015 Average daily volume H1 2014: 1.45 million shares RJF: +62.5% RJF: -14.

  17. Slide 17: Financial Statements

    5. FINANCIAL STATEMENTS

  18. Slide 18: Profit and Loss Account

    PROFIT AND LOSS ACCOUNT H1 2014 H1 2015 (in euro) proforma consolidated Dif. Turnover 79,446,149 81,493,618 2.6% Cost of goods sold -28,286,729 -29,915,983 Gross margin 51,159,420 51,577,635 0.8% Other operating income -36,744 350,851 Overheads -20,253,276 -19,844,426 R&D expenses -2,824,417 -2,710,

  19. Slide 19: Balance Sheet

    BALANCE SHEET (in euro) 30/06/2015 31/12/2014 (in euro) 30/06/2015 31/12/2014 ASSETS EQUITY AND LIABILITIES Non-current assets Equity Goodwill 25,147,584 25,405,979 Share capital 126,428,441 126,428,441 Reserves (4,483,401) (6,791,795) Other intangible assets 32,487,672 32,453,457 Treasury shares (4

  20. Slide 20: Links to Complementary Info

    6. LINKS TO COMPLEMENTARY INFO

  21. Slide 21: Links to Complementary Information

    LINKS TO COMPLEMENTARY INFORMATION  Latest news: www.reigjofre.com/en/news  Webcast on 2014 results: www.reigjofre.com/en/investors/webcasts  Presentation to the Shareholders’ General Meeting: www.reigjofre.com/images/descargas/esp/inversores/presentaciones/2015-06-11-Presentacion- JGA-2015-esp.p

  22. Slide 22: Contact and Investor Relations

    Av. de les Flors 08970 Sant Joan Despi Barcelona, Spain T. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com

Laboratorio Reig Jofre — H1 2015 Earnings Presentation on 6ix